TORONTO, Feb. 25, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"),
an emerging pharmaceutical company, today announced that the Company's
President and Chief Executive Officer, David Lickrish, will present at
the 34th Annual Cowen and Company Health Care Conference at the Boston Marriott
Copley Place in Boston, MA. Highland's presentation is scheduled for
Monday, March 3, 2014 at 11:00am EST.
A live webcast of the presentation can be accessed by visiting www.highlandtherapeutics.com. The webcast will be archived on the Company's website for 30 days.
Mr. Lickrish will provide the investment community with an update on the
clinical development of HLD-200 and HLD-100, Highland's novel
formulations of methylphenidate and amphetamine, respectively, for the
treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). HLD-200
and HLD-100 are designed to be taken at bedtime, to provide clinically
meaningful control of symptoms of ADHD upon wakening and throughout the
Having recently completed an End-of-Phase II meeting with the FDA,
Highland plans to initiate a Phase III trial with HLD-200 in the second
quarter of 2014. Data are expected in the third quarter of 2014.
Methylphenidate is currently sold under the brand name Concerta by
Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company),
Ritalin/Ritalin LA by Novartis Pharmaceuticals Corporation and
Quillivant XR by Pfizer Inc. Amphetamine-based products include
Adderall XR and Vyvanse (both products of Shire plc).
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is an emerging pharmaceutical company that,
through its wholly owned subsidiary Ironshore Pharmaceuticals &
Development, Inc., is leveraging its proprietary technologies to
optimize the delivery of previously approved drug products. The
Company's lead products, HLD-100 and HLD-200, are novel formulations of
the psychostimulants (amphetamine and methylphenidate, respectively)
used to treat ADHD and are being developed to address a prevalent unmet
medical need in the treatment of the disease - the lack of symptom
control during the early morning routine. The clinically meaningful
benefits of Highland's approach are targeted at helping ADHD patients
and their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District's Life
Sciences and Healthcare practice, which provides advisory services and
support to help Ontario life sciences companies grow and commercialize
This press release contains forward-looking information, which reflects
Highland's current expectations regarding future events.
Forward-looking information is based on a number of assumptions and is
subject to a number of risks and uncertainties, many of which are
beyond Highland's control that could cause actual results and events to
differ materially from those that are disclosed in or implied by such
forward-looking information. These forward-looking statements are made
as of the date of this press release and, except as expressly required
by applicable law, Highland assumes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
SOURCE Highland Therapeutics Inc.